Guardant Health

Compare

2,131 Followers

GH Stock Chart & Stats

$72.27

$0.91(2.52%)

At close: Jan 08 4:00 PM EST

$72.27

$0.91(2.52%)

Day’s Range― - ―

52-Week Range$21.28 - $73.31

Previous CloseN/A

Volume639.07K

Average Volume (3M)2.23M

Market Cap

$9.01B

Enterprise Value$7.16B

Total Cash (Recent Filing)$629.14M

Total Debt (Recent Filing)$1.33B

Price to Earnings (P/E)―

Beta1.53

Next Earnings

Feb 19, 2026

EPS Estimate

-0.78

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.74

Shares Outstanding124,705,860

10 Day Avg. Volume2,117,224

30 Day Avg. Volume2,232,326

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.79

Enterprise Value/Revenue8.64

Enterprise Value/Gross Profit13.75

Enterprise Value/Ebitda-19.45

Forecast

1Y Price Target

$81.81

Price Target Upside13.20% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering22

Bulls Say, Bears Say

Bulls Say

Market ExpansionGuardant Health's collaboration agreement with Quest Diagnostics is expected to provide significant return on investment by expanding its test accessibility.

Product InnovationThe launch of new and innovative products, such as the Reveal Ultra test and Shield MCED test, showcases Guardant Health's commitment to advancing its product offerings.

Revenue GrowthGH delivered a strong 3Q as sales grew +34% Y/Y ex-true ups ahead of 22% consensus.

Bears Say

Guardant Health News

This Is Why Guardant Health Stock (GH) Surged 30% Today

Guardant Health ($GH) stock soared 30% today after the precision oncology company delivered a stellar third-quarter earnings report...

8h ago

Guardant Health rises 31.4%

Guardant Health (GH) is up 31.4%, or $22.66 to $94.93. Published first on TheFly – the ultimate source...

11h ago

Midday Fly By: Big Tech reports, Novo tops Pfizer bid for Metsera

The major averages were mixed near noon as investors digest a mix of Big Tech earnings reports, as...

11h ago

Guardant Health rises 30.7%

Guardant Health (GH) is up 30.7%, or $22.17 to $94.44. Published first on TheFly – the ultimate source...

13h ago

Guardant Health price target raised to $110 from $80 at UBS

UBS analyst Dan Leonard raised the firm’s price target on Guardant Health (GH) to $110 from $80 and...

14h ago

Guardant Health price target raised to $100 from $65 at Citi

Citi raised the firm’s price target on Guardant Health (GH) to $100 from $65 and keeps a Buy...

15h ago

Guardant Health price target raised to $100 from $80 at BTIG

BTIG analyst Mark Massaro raised the firm’s price target on Guardant Health (GH) to $100 from $80 and...

15h ago

Guardant Health price target raised to $100 from $75 at Mizuho

Mizuho analyst Bradley Bowers raised the firm’s price target on Guardant Health (GH) to $100 from $75 and...

16h ago

Guardant Health price target raised to $85 from $70 at Barclays

Barclays raised the firm’s price target on Guardant Health (GH) to $85 from $70 and keeps an Overweight...

16h ago

Guardant Health price target raised to $100 from $75 at Canaccord

Canaccord analyst Kyle Mikson raised the firm’s price target on Guardant Health (GH) to $100 from $75 and...

16h ago

Closing Bell Movers: Meta sinks, Alphabet jumps after earnings

In the opening hours of the evening session, U.S. equity futures are marginally lower, with S&P 500, Nasdaq...

1d ago

EXAS, GH, PLTR, SOFI: Cathie Wood Invests $5.5M in Exact Sciences, Trims Stakes in Guardant, Palantir, SoFi, and Other Big Names

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) revealed several key portfolio moves for Monday, October 20, 2025, showing renewed focus on...

10d ago

EXAS

Guardant Health’s Q3 2025 Earnings: Strong Growth Amid Challenges

Guardant Health (($GH)) has held its Q3 earnings call. Read on for the main highlights of the call....

2h ago

Guardant Health Reports Strong Q3 2025 Growth

Guardant Health ( ($GH) ) has released its Q3 earnings. Here is a breakdown of the information Guardant...

22h ago

GH FAQ

What was Guardant Health’s price range in the past 12 months?

Guardant Health lowest stock price was $21.28 and its highest was $73.31 in the past 12 months.

What is Guardant Health’s market cap?

Guardant Health’s market cap is $9.01B.

When is Guardant Health’s upcoming earnings report date?

Guardant Health’s upcoming earnings report date is Feb 19, 2026 which is in 111 days.

How were Guardant Health’s earnings last quarter?

Guardant Health released its earnings results on Oct 29, 2025. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.79 by $0.05.

Is Guardant Health overvalued?

According to Wall Street analysts Guardant Health’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Guardant Health pay dividends?

Guardant Health does not currently pay dividends.

What is Guardant Health’s EPS estimate?

Guardant Health’s EPS estimate is -0.78.

How many shares outstanding does Guardant Health have?

Guardant Health has 124,705,860 shares outstanding.

What happened to Guardant Health’s price movement after its last earnings report?

Guardant Health reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.79. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Guardant Health?

Currently, no hedge funds are holding shares in GH

Guardant Health Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-17.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Guardant Health

Guardant Health (GH) is a precision oncology company focused on transforming cancer care through innovative blood testing technology. Operating primarily in the healthcare sector, Guardant Health specializes in non-invasive genomic sequencing and analysis of circulating tumor DNA (ctDNA) to aid in cancer diagnosis, treatment selection, and monitoring. Its core products include the Guardant360 and GuardantOMNI tests, which offer comprehensive genomic insights to oncologists and help guide personalized treatment plans for cancer patients.

Guardant Health (GH) Earnings & Revenues

Historic Earnings Reports

GH Company Deck

GH Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Guardant Health demonstrated strong revenue growth and operational achievements in its oncology and Shield testing businesses. Strategic partnerships and improved gross margins further strengthen the company's position. However, increased operating expenses and uncertainties in future reimbursement and guideline inclusion present challenges.View all GH earnings summaries

GH Revenue Breakdown

91.19% Precision oncology testing

8.81% Development services and other

GH Stock 12 Month Forecast

Average Price Target

$81.81

▲(13.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","66":"$66","111":"$111","43.5":"$43.5","88.5":"$88.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81.81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$81.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,43.5,66,88.5,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.65,66.29230769230769,69.93461538461538,73.57692307692308,77.21923076923076,80.86153846153846,84.50384615384615,88.14615384615385,91.78846153846153,95.43076923076923,99.07307692307691,102.71538461538461,106.3576923076923,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.65,64.12384615384616,65.59769230769231,67.07153846153847,68.54538461538462,70.01923076923077,71.49307692307693,72.96692307692308,74.44076923076923,75.91461538461539,77.38846153846154,78.8623076923077,80.33615384615385,{"y":81.81,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.65,62.44615384615385,62.24230769230769,62.03846153846154,61.83461538461538,61.63076923076923,61.426923076923075,61.223076923076924,61.01923076923077,60.815384615384616,60.61153846153846,60.40769230769231,60.20384615384616,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.52,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >